Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
2015
74
LTM Revenue n/a
LTM EBITDA -$141M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Disc Medicine has a last 12-month revenue of n/a and a last 12-month EBITDA of -$141M.
In the most recent fiscal year, Disc Medicine achieved revenue of n/a and an EBITDA of -$91.0M.
Disc Medicine expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Disc Medicine valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | XXX |
Gross Profit | n/a | n/a | n/a | XXX | XXX |
Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
EBITDA | -$47.4M | -$91.0M | -$132M | -$141M | XXX |
EBITDA Margin | -Infinity% | -Infinity% | -Infinity% | -Infinity% | XXX |
Net Profit | -$71.9M | -$46.8M | -$76.4M | XXX | XXX |
Net Margin | -Infinity% | -Infinity% | -Infinity% | XXX | XXX |
Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 10, 2025, Disc Medicine's stock price is $55.
Disc Medicine has current market cap of $1.9B, and EV of $1.4B.
See Disc Medicine trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$1.4B | $1.9B | XXX | XXX | XXX | XXX | $-4.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 10, 2025, Disc Medicine has market cap of $1.9B and EV of $1.4B.
Disc Medicine's trades at n/a LTM EV/Revenue multiple, and -9.9x LTM EBITDA.
Analysts estimate Disc Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Disc Medicine and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $1.4B | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | XXX | XXX |
EV/EBITDA | -10.6x | XXX | XXX | XXX |
P/E | -16.5x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDisc Medicine's NTM/LTM revenue growth is Infinity%
Disc Medicine's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Disc Medicine's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Disc Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Disc Medicine and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | n/a | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | 45% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Disc Medicine acquired XXX companies to date.
Last acquisition by Disc Medicine was XXXXXXXX, XXXXX XXXXX XXXXXX . Disc Medicine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Disc Medicine founded? | Disc Medicine was founded in 2015. |
Where is Disc Medicine headquartered? | Disc Medicine is headquartered in United States of America. |
How many employees does Disc Medicine have? | As of today, Disc Medicine has 74 employees. |
Who is the CEO of Disc Medicine? | Disc Medicine's CEO is Dr. John D. Quisel, J.D.,PhD. |
Is Disc Medicine publicy listed? | Yes, Disc Medicine is a public company listed on NAS. |
What is the stock symbol of Disc Medicine? | Disc Medicine trades under IRON ticker. |
When did Disc Medicine go public? | Disc Medicine went public in 2021. |
Who are competitors of Disc Medicine? | Similar companies to Disc Medicine include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Disc Medicine? | Disc Medicine's current market cap is $1.9B |
What is the current EBITDA of Disc Medicine? | Disc Medicine's last 12-month EBITDA is -$141M. |
What is the current EV/EBITDA multiple of Disc Medicine? | Current EBITDA multiple of Disc Medicine is -9.9x. |
Is Disc Medicine profitable? | Yes, Disc Medicine is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.